Just slowly re-read the latest 8-K. How on Earth
Post# of 15624
(Total Views: 675)
Posted On: 04/08/2017 12:29:54 PM
Just slowly re-read the latest 8-K. How on Earth did I miss this Gem:
"A wide and in-depth multi-layer clinical study on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease."
In my DD of psoriasis, I have learned that psoriasis often causes Depression . This is well documented: https://scholar.google.com/scholar?q=comorbid...depression
IF I understand this correctly, what we will see in the First wave is the over-the-counter CBD/THC cream for psoriasis (e.g., one that people will have to pay for out of pocket). Second wave will be an FDA approved cream for psoriasis (e.g., one that insurance would cover). Third wave will be an FDA approved sublingual tablet to treat patients with psoriasis and depression .
This is huge. OWCP's Third wave approach is a novel solution for any person with both psoriasis and depression, because of cannabis' unique anti-inflammatory and psychoactive properties.
(Then again, I could have it wrong. It could very well be First wave is OTC psoriasis cream and Second wave is sublingual tablet for psoriasis and depression.)
This is a well into 2019 at the rate the FDA approves things today, but nonetheless it's a huge new entry on OWCP's pipeline.
Someone who has psoriasis and depression today is taking one of the existing gold standard oral psoriasis medications and gold standard anti-depression meds. The combined side effects from these meds are frankly horrendous- kidney damage, liver damage, fatigue, libido, weight gain, and suicidal thoughts.
We know cannabis is side effect free and we know good, ethical doctors will be happy to offer patients a single new med for two indications that would otherwise require two meds.
It's been a stormy week, but to me this is a new lighthouse on the horizon.
"A wide and in-depth multi-layer clinical study on Psoriasis and psychological aspects is targeted to start next year, 2018, after collection of data from patients to carefully plan the targets of such a unique study that will show a combination of cannabinoids treatments for a specific disease."
In my DD of psoriasis, I have learned that psoriasis often causes Depression . This is well documented: https://scholar.google.com/scholar?q=comorbid...depression
IF I understand this correctly, what we will see in the First wave is the over-the-counter CBD/THC cream for psoriasis (e.g., one that people will have to pay for out of pocket). Second wave will be an FDA approved cream for psoriasis (e.g., one that insurance would cover). Third wave will be an FDA approved sublingual tablet to treat patients with psoriasis and depression .
This is huge. OWCP's Third wave approach is a novel solution for any person with both psoriasis and depression, because of cannabis' unique anti-inflammatory and psychoactive properties.
(Then again, I could have it wrong. It could very well be First wave is OTC psoriasis cream and Second wave is sublingual tablet for psoriasis and depression.)
This is a well into 2019 at the rate the FDA approves things today, but nonetheless it's a huge new entry on OWCP's pipeline.
Someone who has psoriasis and depression today is taking one of the existing gold standard oral psoriasis medications and gold standard anti-depression meds. The combined side effects from these meds are frankly horrendous- kidney damage, liver damage, fatigue, libido, weight gain, and suicidal thoughts.
We know cannabis is side effect free and we know good, ethical doctors will be happy to offer patients a single new med for two indications that would otherwise require two meds.
It's been a stormy week, but to me this is a new lighthouse on the horizon.
(2)
(0)OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼